CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphoma

The infusion of chimeric antigen receptor (CAR) T cells that target specific tumor-associated antigens is a promising strategy that has exhibited encouraging results in clinical trials. However, few studies have focused on the effectiveness and safety of CD20 CAR T cells in rituximab-refractory/rela...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cytotherapy (Oxford, England) England), 2022-10, Vol.24 (10), p.1026-1034
Hauptverfasser:	Cheng, Qian, Tan, Jingwen, Liu, Rui, Kang, Liqing, Zhang, Yi, Wang, Erhua, Li, Ying, Zhang, Jian, Xiao, Han, Xu, Nan, Li, Minghao, Yu, Lei, Li, Xin
Format:	Artikel
Sprache:	eng
Schlagworte:	CAR T-cell therapy CD20 Cytokine release syndrome (CRS) Non-Hodgkin lymphoma Rituximab
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!